MA37647A1 - Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci - Google Patents

Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci

Info

Publication number
MA37647A1
MA37647A1 MA37647A MA37647A MA37647A1 MA 37647 A1 MA37647 A1 MA 37647A1 MA 37647 A MA37647 A MA 37647A MA 37647 A MA37647 A MA 37647A MA 37647 A1 MA37647 A1 MA 37647A1
Authority
MA
Morocco
Prior art keywords
salts
compounds
producing hydroxylated
cyclopentapyrimidine compounds
hydroxylated cyclopentapyrimidine
Prior art date
Application number
MA37647A
Other languages
English (en)
Inventor
Srinivasan Babu
Francis Gosselin
Yingqing Ran
Travis Remarchuk
Scott J Savage
Jeffrey Stults
Herbert Yajima
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA37647A1 publication Critical patent/MA37647A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne de nouveaux procédés pour fabriquer et purifier des sels de composés de cyclopentapyrimidine hydroxylée, qui sont utiles en tant qu'inhibiteurs d'akt utilisés dans le traitement de maladies telles que le cancer, comprenant le sel monochlorhydrate de (s)-2-(4-chlorophényl)-1-(4-((5r,7r)-7-hydroxy-5-méthyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl)pipérazin-1-yl)-3-(isopropylamino)propan-1-one.
MA37647A 2012-05-17 2013-05-17 Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci MA37647A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261648535P 2012-05-17 2012-05-17
PCT/US2013/041695 WO2013173784A1 (fr) 2012-05-17 2013-05-17 Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci

Publications (1)

Publication Number Publication Date
MA37647A1 true MA37647A1 (fr) 2016-03-31

Family

ID=48534508

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37647A MA37647A1 (fr) 2012-05-17 2013-05-17 Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci

Country Status (17)

Country Link
US (1) US9315471B2 (fr)
EP (1) EP2850200A1 (fr)
JP (1) JP6355625B2 (fr)
KR (1) KR102123131B1 (fr)
CN (1) CN104471070B (fr)
AU (1) AU2013262521B2 (fr)
BR (1) BR112014028573B1 (fr)
CA (1) CA2873661C (fr)
IL (1) IL235699B (fr)
MA (1) MA37647A1 (fr)
MX (1) MX354373B (fr)
MY (1) MY169029A (fr)
NZ (1) NZ702950A (fr)
RU (1) RU2642311C2 (fr)
SG (1) SG11201407591PA (fr)
WO (1) WO2013173784A1 (fr)
ZA (1) ZA201409226B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2858989T3 (da) 2012-05-17 2020-06-02 Genentech Inc Amorf form af en AKT-hæmmende pyrimidinyl-cyclopentan-forbindelse, sammensætninger deraf og fremgangsmåder dertil
CN104520263B (zh) 2012-05-17 2016-11-09 基因泰克公司 制备氨基酸化合物的方法
DK2861582T3 (en) 2012-05-17 2016-08-22 Array Biopharma Inc A process for preparing hydroxylated compounds cyclopentylpyrimidin
JP6214636B2 (ja) 2012-05-17 2017-10-18 アレイ バイオファーマ、インコーポレイテッド ヒドロキシル化シクロペンチルピリミジン化合物を作製するためのプロセス
HRP20231100T1 (hr) 2013-11-15 2023-12-22 F. Hoffmann - La Roche Ag Postupci za proizvodnju pirimidinilciklopentan spojeva
SG10201806450SA (en) 2014-09-26 2018-09-27 Hoffmann La Roche PROCESSES FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS
CA3032233C (fr) 2016-08-10 2021-09-14 F. Hoffmann-La Roche Ag Compositions pharmaceutiques comprenant des inhibiteurs de la proteine kinase akt
CN110268067A (zh) * 2016-08-16 2019-09-20 伊美格生物科学公司 用于产生立体异构纯的氨基环丙烷的组合物和方法
WO2019122421A1 (fr) * 2017-12-22 2019-06-27 Astrazeneca Ab Réduction stéréosélective de cétone à l'aide d'une enzyme cétoréductase
CA3186565A1 (fr) * 2020-07-22 2022-01-27 Lei Miao Composition de dosage unitaire d'inhibiteur d'akt
US20230271958A1 (en) * 2020-07-22 2023-08-31 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. SALT AND CRYSTAL FORM OF DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATE
WO2023043869A1 (fr) 2021-09-15 2023-03-23 Teva Pharmaceuticals International Gmbh Formes à l'état solide de citrate d'ipatasertib

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2178829A1 (fr) 1993-12-12 1995-06-15 Yigal Cohen Nouveau procede servant a proteger des vegetaux des infections fongiques
EP0973396A4 (fr) 1997-04-07 2001-02-07 Merck & Co Inc Procede de traitement du cancer
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
AU1302999A (en) 1997-11-04 1999-05-24 Eli Lilly And Company Ketoreductase gene and protein from yeast
EP0982300A3 (fr) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines comme antagonistes du recepteur histamine H3 et leur application thérapeutique
CA2363169A1 (fr) 1999-03-03 2000-09-08 Merck & Co., Inc. Inhibiteurs de la prenyle-proteine transferase
WO2001022963A1 (fr) 1999-09-27 2001-04-05 Merck & Co., Inc. Procede de prevention de l'osteoporose
DE10119274A1 (de) * 2001-04-20 2002-10-31 Juelich Enzyme Products Gmbh Enzymatisches Verfahren zur enantioselektiven Reduktion von Ketoverbindungen
WO2004108673A2 (fr) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibiteurs du papillomavirus
AU2006258124B8 (en) * 2005-06-10 2010-01-07 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
UA95641C2 (xx) 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
CN101855342B (zh) * 2007-09-13 2013-07-10 科德克希思公司 用于还原苯乙酮的酮还原酶多肽
US20100298289A1 (en) 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
EP2240455B1 (fr) 2008-01-09 2012-12-26 Array Biopharma, Inc. Pyrimidyl cyclopentane hydroxylé en tant qu'inhibiteur de protéine kinase akt
EP2419404B1 (fr) 2009-04-15 2015-11-04 AbbVie Inc. Composes anti virale
AU2010310786B2 (en) 2009-10-23 2014-03-27 Eli Lilly And Company AKT inhibitors
US9050334B2 (en) 2010-07-16 2015-06-09 Innov88 Llc MIF inhibitors and their uses
WO2012177925A1 (fr) 2011-06-21 2012-12-27 The Board Institute, Inc. Inhibiteurs akt pour le traitement d'un cancer exprimant un gène de fusion magi3 - akt3
CN104520263B (zh) 2012-05-17 2016-11-09 基因泰克公司 制备氨基酸化合物的方法
DK2861582T3 (en) 2012-05-17 2016-08-22 Array Biopharma Inc A process for preparing hydroxylated compounds cyclopentylpyrimidin
JP6214636B2 (ja) 2012-05-17 2017-10-18 アレイ バイオファーマ、インコーポレイテッド ヒドロキシル化シクロペンチルピリミジン化合物を作製するためのプロセス
CA2889855A1 (fr) 2012-11-01 2014-05-08 Robert S. Katz Methodes de traitement de la fibromyalgie
EP2956441A4 (fr) 2013-02-18 2016-11-02 Scripps Research Inst Modulateurs des récepteurs de la vasopressine à pouvoir thérapeutique
US10131637B2 (en) 2013-03-15 2018-11-20 Shifa Biomedical Corporation Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases

Also Published As

Publication number Publication date
HK1208500A1 (en) 2016-03-04
NZ702950A (en) 2016-09-30
CN104471070B (zh) 2018-09-25
JP2015518715A (ja) 2015-07-06
US9315471B2 (en) 2016-04-19
US20150099880A1 (en) 2015-04-09
AU2013262521A1 (en) 2015-01-22
KR20150018579A (ko) 2015-02-23
MX354373B (es) 2018-02-28
IL235699B (en) 2018-12-31
RU2014151014A (ru) 2016-07-10
IL235699A0 (en) 2015-01-29
SG11201407591PA (en) 2015-01-29
AU2013262521B2 (en) 2017-03-02
WO2013173784A1 (fr) 2013-11-21
EP2850200A1 (fr) 2015-03-25
RU2642311C2 (ru) 2018-01-24
BR112014028573A2 (pt) 2018-04-24
MX2014013855A (es) 2016-03-21
BR112014028573B1 (pt) 2021-11-16
MY169029A (en) 2019-02-04
KR102123131B1 (ko) 2020-06-15
CA2873661C (fr) 2020-07-21
JP6355625B2 (ja) 2018-07-11
CA2873661A1 (fr) 2013-11-21
ZA201409226B (en) 2017-09-27
CN104471070A (zh) 2015-03-25

Similar Documents

Publication Publication Date Title
MA37649B1 (fr) Procédé de fabrication de composés cyclopentylpyrimidines hydroxylées
MY169029A (en) Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
WO2010147898A3 (fr) Inhibiteurs à petite molécule de la tyrosine kinase de la rate (syk)
JOP20190151B1 (ar) مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان
MX368042B (es) COMPUESTOS ÚTILES COMO INHIBIDORES DE CINASA RELACIONADA CON ATAXIA TELANGIECTASIA MUTADA Y Rad3 (ATR).
PE20180050A1 (es) Heterociclos biciclicos como inhibidores de fgfr 4
NZ700580A (en) Compounds useful as inhibitors of atr kinase and combination therapies thereof
MX2016007371A (es) Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados.
IN2014KN00943A (fr)
UA111854C2 (uk) Способи і проміжні сполуки для отримання інгібіторів jak
NO20083918L (no) Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser
EA201270480A1 (ru) Новые соединения
EA201391528A1 (ru) Ингибиторы тирозинкиназы
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
MA37751A1 (fr) Procédé de préparation de composés d'acides aminés
MX2018002885A (es) Sales de inhibidor de pim cinasa.
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
MA39170A1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
JP2011509306A5 (fr)
EA201170736A1 (ru) Синтез и новые солевые формы (r)-3-((e)-2-(пирролидин-3-ил)винил)-5-(тетрагидропиран-4-илокси) пиридина
SG10201806450SA (en) PROCESSES FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS
MA39020A1 (fr) Sels de l'acide 1 -(3-méthyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluorométhyl)-2,3-dihydro-lh-indén-1 -yl]-1,2,3,4-tétrahydropyrimidine-5-carboxylique
MX384986B (es) Sal y formas polimorficas de (3r,4s)-l-((4-amino-5h-pirrolo[3,2-d]pirimidin-7-il)metil)-4(metiltiometil)pirodin-3-ol(mtdia).
MA44503B1 (fr) Composés de pyrrolotriazine en tant qu'inhibiteurs de tam
EA201990404A1 (ru) Улучшенные формы селективного ингибитора pi3k-дельта для применения в фармацевтических препаратах